Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel

作者：Brenda Crabtree‐Ramírez, Donna M. Jacobsen, Jennifer Hoy, Susan Buchbinder, Michael S. Saag, Melanie Thompson, Jean‐Michel Molina, Joseph J. Eron, Clara Lehmann, Ellen Eaton, Raphael J. Landovitz, Roger Bedimo, Carlos del Rı́o, Paul E. Sax, Davey M. Smith, Rajesh T. Gandhi, Constance A. Benson, Sandra A. Springer, Huldrych F. Günthard · 发表于：Carolina Digital Repository (University of North Carolina at Chapel Hill) · 年份：2024 · DOI：10.17615/zw8g-1v62 · 被引用次数：3 · 研究领域：HIV/AIDS drug development and treatment、HIV/AIDS Research and Interventions、HIV-related health complications and treatments

New data and new antiretroviral drugs and formulations continue to become available for the prevention and management of HIV infection. To provide updated recommendations for HIV treatment and clinical management and HIV prevention. A panel of volunteer expert physician scientists were appointed to provide updated consensus recommendations for 2024. Relevant evidence in the literature since the last report was identified from PubMed and Embase searches (which initially yielded 3998 unique citations, of which 249 were considered relevant); from ongoing monitoring of the literature by the panel members; from data submitted by product manufacturers; and from studies presented at peer-reviewed scientific conferences between June 2022 and October 2024. Antiretroviral therapy continues to be recommended for all individuals with HIV. For most people with HIV, initial regimens composed of an integrase strand transfer inhibitor (InSTI), specifically bictegravir or dolutegravir, with 2 (and in some cases 1) nucleoside or nucleotide reverse transcriptase inhibitors are recommended. Recommendations are made for those with particular clinical circumstances, such as pregnancy and active opportunistic diseases, as well as for those unable to take InSTIs. Regimens may need to be changed for virologic failure, adverse effects, convenience, or cost, among other reasons. Long-acting injectable therapy is available for those who prefer not to take daily oral medications and for people struggling...